Kestra Medical Technologies (KMTS) said Monday it plans to offer 5.5 million common shares via an underwritten public offering.

The company will grant underwriters a 30-day option to purchase up to an additional 825,000 shares at the public offering price, excluding underwriting discounts and commissions, it said.

Kestra plans to use the proceeds from the offering to support sales and marketing, ongoing commercialization, research and development, clinical studies, and working capital and general corporate purposes, the company said.

BofA Securities, Piper Sandler, JPMorgan, Goldman Sachs, and Wells Fargo Securities are serving as bookrunners for the offering, Kestra said.

Kestra shares were down more than 4% in recent Monday pre-bell activity.